% of total paths
(a)
Mild MS Patients
Proteomics to Clinical
Clinical
13%
6%
0%
Imaging
35%
17%
0%
Cytomics
24%
12%
0%
Proteomics
20%
10%
0%
Genomics
0%
0%
0%
Edges
21%
10%
0%
% of total paths
(b)
Severe MS Patients
Proteomics to Clinical
Clinical
21%
10%
0%
Imaging
26%
13%
0%
Cytomics
14%
7%
0%
Proteomics
30%
15%
0%
Genomics
0%
0%
0%
Edges
16%
8%
0%
% of total paths
(c)
Mild MS Patients
Genomics to Clinical
Clinical
45%
22%
0%
Imaging
30%
15%
0%
Cytomics
35%
17%
0%
Proteomics
50%
25%
0%
Genomics
85%
42%
0%
Edges
85%
42%
0%
% of total paths
(d)
Severe MS Patients
Genomics to Clinical
Clinical
19%
9%
0%
Imaging
25%
12%
0%
Cytomics
32%
16%
0%
Proteomics
81%
40%
0%
Genomics
91%
45%
0%
Edges
86%
43%
0%
% of total paths
(e)
Mild MS Patients
Cytomics to Clinical
Clinical
18%
9%
0%
Imaging
20%
10%
0%
Cytomics
24%
12%
0%
Proteomics
0%
0%
0%
Genomics
0%
0%
0%
Edges
24%
12%
0%
% of total paths
(f)
Severe MS Patients
Cytomics to Clinical
Clinical
24%
12%
0%
Imaging
25%
12%
0%
Cytomics
26%
13%
0%
Proteomics
0%
0%
0%
Genomics
0%
0%
0%
Edges
20%
10%
0%

(a)
Relapse-Remitting MS
Proteomics to Clinical
(b)
Progressive MS
Proteomics to Clinical
(c)
Relapse-Remitting MS
Genomics to Clinical
(d)
Progressive MS
Genomics to Clinical
(e)
Relapse-Remitting MS
Cytomics to Clinical
(f)
Progressive MS
Cytomics to Clinical
% of total paths
Clinical
Imaging
Cytomics
Proteomics
Genomics
Edges

(a)
Low Efficacy Treatment
Proteomics to Clinical
(b)
High Efficacy Treatment
Proteomics to Clinical
(c)
Low Efficacy Treatment
Genomics to Clinical
(d)
High Efficacy Treatment
Genomics to Clinical
(e)
Low Efficacy Treatment
Cytomics to Clinical
(f)
High Efficacy Treatment
Cytomics to Clinical
% of total paths
Clinical
Imaging
Cytomics
Proteomics
Genomics
Edges